BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 16821594)

  • 1. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.
    Jiang J; Xu N; Wu C; Deng H; Lu M; Li M; Xu B; Wu J; Wang R; Xu J; Nilsson-Ehle P
    Anticancer Res; 2006; 26(3B):2237-42. PubMed ID: 16821594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
    Wu C; Jiang J; Shi L; Xu N
    Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas.
    Weng DS; Zhou J; Zhou QM; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Wu PH; Xia JC
    J Immunother; 2008 Jan; 31(1):63-71. PubMed ID: 18157013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
    Niu Q; Wang W; Li Y; Qin S; Wang Y; Wan G; Guan J; Zhu W
    Int Immunopharmacol; 2011 Apr; 11(4):449-56. PubMed ID: 21215350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical observation on adoptive immunotherapy with autologous cytokine-induced killer cells for advanced malignant tumor].
    Chen FX; Liu JQ; Zhang NZ; Gong XJ; Zhang GL; Xu YM; Zhou ZH; Wang T; Huang J
    Ai Zheng; 2002 Jul; 21(7):797-801. PubMed ID: 12479111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma].
    Zhou QM; Wu PH; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 Nov; 25(11):1414-8. PubMed ID: 17094912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
    Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial.
    Yang B; Lu XC; Yu RL; Chi XH; Liu Y; Wang Y; Dai HR; Zhu HL; Cai LL; Han WD
    Hematol Oncol; 2012 Sep; 30(3):115-22. PubMed ID: 22972689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Growth inhibition of human hepatocellular carcinoma xenograft in nude mice by combined treatment with human cytokine-induced killer cells and chemotherapy].
    Shi M; Yao L; Wang FS; Lei ZY; Zhang B; Li WL; Liu JC; Tang ZR; Zhou GD
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):465-8. PubMed ID: 15555334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients].
    Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
    Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
    Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
    Zhu BQ; Ju SW; Shu YQ
    Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
    Sangiolo D; Martinuzzi E; Todorovic M; Vitaggio K; Vallario A; Jordaney N; Carnevale-Schianca F; Capaldi A; Geuna M; Casorzo L; Nash RA; Aglietta M; Cignetti A
    Int Immunol; 2008 Jul; 20(7):841-8. PubMed ID: 18469328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
    Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
    Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of cytokine-induced killer cells against human lung cancer.
    Kim HM; Lim J; Park SK; Kang JS; Lee K; Lee CW; Lee KH; Yun MJ; Yang KH; Han G; Kwon SW; Kim Y; Han SB
    Int Immunopharmacol; 2007 Dec; 7(13):1802-7. PubMed ID: 17996691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
    Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
    Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.
    Tsavaris NB; Katsoulas HL; Kosmas C; Papalambros E; Gouveris P; Papantoniou N; Rokana S; Kosmas N; Skopeliti M; Tsitsilonis OE
    Oncology; 2004; 67(5-6):403-10. PubMed ID: 15713997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
    Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
    Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells.
    Kim YJ; Lim J; Kang JS; Kim HM; Lee HK; Ryu HS; Kim JY; Hong JT; Kim Y; Han SB
    Arch Pharm Res; 2010 Nov; 33(11):1789-95. PubMed ID: 21116782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.